TC-99M NGA IN THE EVALUATION OF LIVER DISEASE

TC-99M NGA 在肝脏疾病评估中的应用

• 批准号: 3232966
• 负责人: ROBERT CHARLES STADALNIK
• 金额: $ 26.87万
• 依托单位: UNIVERSITY OF CALIFORNIA AT DAVIS
• 依托单位国家: 美国
• 财政年份: 1984
• 资助国家: 美国
• 起止时间: 1984-12-01 至 1992-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3232966
• 关键词: antipyrine; biopsy; diagnosis design /evaluation; human subject; image processing; liver cells; liver disorder diagnosis; liver function; positron emission tomography; prognosis; radionuclide diagnosis; radiopharmacology; radiotracer; single photon emission computed tomography; statistics /biometry; technetium

The long term goal of our research is to determine the role of TcNGA parameter estimates of liver function and their relationship to liver disease, both from a diagnostic and prognostic viewpoint. We plan to evaluate the usefulness of TcNGA as a quantitative measure of liver function in four areas: 1) prognosis in liver disease, 2) therapeutic effect in liver disease, 3) classification of disease presence and disease category, and 4) regional versus global estimation of liver function. Aims, 1, 2 and 3 will be accomplished using modern statistical analysis. Using the Cox regression models, information on variables associated with prognosis and therapeutic effect in liver disease can be obtained, as well as a more precise estimation of therapy-dependent prognosis in the individual patient. With the discriminant analysis method, classification of disease presence and disease category can be accomplished. Aim 4 will be a preliminary evaluation using planar, SPECT, and PET NGA imaging techniques. This will address the question of whether regional estimates of liver function add significant prognostic or therapeutic information. It will also address the advantages and disadvantages of PET versus SPECT versus planar NGA kinetic modeling. In addition, the 14C-aminopyrine breath test and the endogenous ligand assay will be performed, and when possible, we will obtain and assay liver biopsy samples for determination of hepatic binding protein concentration. These values will be correlated with the NGA functional parameter estimates.

我们研究的长期目标是确定TcNGA的作用 肝功能参数估计及其与肝脏的关系 疾病，从诊断和预后的角度都是如此。我们计划 TcNGA作为肝脏定量指标的价值评价 在四个方面的作用：1)肝脏疾病的预后，2)治疗 对肝脏疾病的影响，3)疾病存在和疾病的分类 类别，以及4)肝功能的地区性和全球性评估。 目标1、2和3将使用现代统计分析来实现。 使用COX回归模型，与以下变量相关的信息 也可以获得肝病的预后和治疗效果。 作为一种更准确的估计依赖于治疗的预后的方法 个别病人。用判别分析的方法，分类 可以完成疾病存在和疾病类别的评估。 目标4将使用平面、SPECT和PET NGA进行初步评估 成像技术。这将解决地区性是否 对肝功能的评估增加了重要的预后或治疗 信息。它还将讨论PET的优势和劣势 与SPECT和平面NGA动力学建模的对比。 此外，~(14)C-氨基比林呼气试验和内源性配体 将进行化验，如有可能，我们将获取并化验肝脏 用于测定肝脏结合蛋白浓度的活检样本。 这些值将与NGA功能参数相关 估计。